Kornimate/medical-research-clean huggingface dataset:
transdermal patch for buprenorphine induction during pregnancy (patch bridge)

Conditions: Opioid Use Disorder; Pregnancy Related; Pregnancy, High Risk; Pregnancy Complications; Buprenorphine Withdrawal

Summary: the goal of this clinical trial is to compare buprenorphine patch for induction (starting) of buprenorphine in pregnant patients with opioid use disorder. the main questions it aims to answer are: 1. is there a buprenorphine induction method that results in the least moderate-to-severe opioid withdrawal symptoms in pregnant patients with opioid use disorder? 2. is there a buprenorphine induction method that results in a higher treatment success rate? under normal circumstances, patients who are planning to start sublingual (under the tongue) buprenorphine for opioid use disorder must first go into withdrawal to start the medication safely. study participants will be given a buprenorphine patch during the required withdrawal period before starting sublingual treatment, and be surveyed daily by phone to assess their withdrawal symptoms. they will also be followed at prenatal appointments to evaluate treatment success based on urine drug screen results. researchers will compare patients receiving no buprenorphine patch according to the current standard care protocol.


Eligibility criteria:
inclusion criteria: * viable pregnancy * meet diagnostic criteria for opioid use disorder * receive prenatal care through opioid use disorder specific clinic at our institution * opioid use within 24 hours prior to presentation * desire treatment with buprenorphine exclusion criteria: * patients already receiving treatment for opioid use disorder * history of prior induction attempt with buprenorphine * active withdrawal at time of presentation * medical contraindication to buprenorphine * requiring immediate hospitalization
comparison of the effects of neostigmine with sugammadex on postoperative nausea and vomiting.

Conditions: Incidence of Postoperative Nausea and Vomiting

Summary: postoperative nausea and vomiting is one of most common complications after general anesthesia. female sex, history of postoperative nausea and vomiting, motion sickness, non smoker status, opioid administration are known as risk factors for developing postoperative nausea and vomiting. it has been suggest that antagonism of residual neuromuscular block with a mixture of neostigmine and atropine at the end of the surgery increases the risk of postoperative nausea and vomiting. sugammadex is a very safe drug with almost no serious adverse effects. the known adverse effects include slight coughing, movement, an altered taste sensation in the mouth, transient prolongation of the qt interval, hypersensitivity, and a short term prolongation of the activated partial thromboplastin time. the aim of this study was to compare the sugammadex versus neostigmine plus atropine for reversal of rocuronium induced neuromuscular blockade in terms of incidence of postoperative nausea and vomiting.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status 1 and 2 * endotracheal intubation and general anesthesia scheduled for elective surgery exclusion criteria: * age \ 65 years * pregnancy * refusal to participate and patients already participating in another study * allergy to study drugs * communication difficulty * psychiatric and neurological disorders * use of analgesics or sedative or antiemetic drugs within 24 hours before surgery. * emergency surgery * history of drug or alcohol abuse * asa 3 and above * patients with vertigo * laparoscopic surgery, oncologic surgery, strabismus and mid ear surgery neurosurgery, gynecologic surgery, breast surgery
perineal body length and perineal lacerations

Conditions: Perineal Laceration Involving Skin; Delivery; Trauma

Summary: the aim of this study was to evaluate the relationship between perineal body length and perineal laceration risk in primigravid patients. primigravid women with singleton pregnancies in the first stage of labor at the 35th week of gestation were included in the study. the peineal body length of the patients was measured by the same physician.

after 35 weeks of gestation, nulliparous women with single gestation were included in the study and genital hiatus and perineal body measurements were taken. the presence and degree of perineal laceration after birth were determined. correlation of genital hiatus and perineal body measurements with perineal laceration risk were evaluated. after birth, vaginal laceration, oxytocin use, fetal birth weight, the presence of episiotomy were recorded.

Eligibility criteria:
inclusion criteria: -primigravid women with singleton pregnancy at over 35th week exclusion criteria: * the story of operative vaginal birth; * caesarean section; * breech presentation; * those with a history of anorectal surgery or trauma

Keywords: perineal laceration obstetric trauma
citrulline allo. evaluation of citrullinemia as a marker of bowel damage after allogeneic bone marrow transplantation in children

Conditions: Benign Disease

Summary: determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

30 children included. dosage of citrullinemia on day -7, day 0 and every week up to 100 days after bmt. histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days). two groups of patients regarding on digestive involvement. comparison of the values of citrullinemia between these two groups.

Eligibility criteria:
inclusion criteria: * 0 to 18 years * allogeneic bone marrow transplantation for malignant or benign disease * affiliation to french sécurité sociale * parent's consent exclusion criteria: * severe gastro-intestinal involvement before transplant * previous digestive surgery

Keywords: children allogeneic bone marrow transplantation intestinal damage citrulline graft versus host disease 0 to 18 years old
a study of avutometinib (vs-6766) v. avutometinib (vs-6766) + defactinib in recurrent low-grade serous ovarian cancer with and without a kras mutation

Conditions: Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer

Summary: this study will assess the safety and efficacy of avutometinib (vs-6766) monotherapy and in combination with defactinib in subjects with recurrent low-grade serous ovarian cancer (lgsoc)

this is a multicenter, randomized, open-label phase 2 study designed to evaluate safety and tolerability and preliminary efficacy of avutometinib (vs-6766) versus avutometinib (vs-6766) in combination with defactinib in subjects with molecularly profiled recurrent lgsoc.

Eligibility criteria:
inclusion criteria: * histologically proven lgsoc (ovarian, peritoneal) * progression or recurrence of lgsoc after at least one prior systemic therapy for metastatic disease. * measurable disease according to recist 1.1 * an eastern cooperative group (ecog) performance status ≤ 1. * adequate organ function * adequate recovery from toxicities related to prior treatments * agreement to use highly effective method of contraceptive, if necessary exclusion criteria: * systemic anti-cancer therapy within 4 weeks of the first dose of study therapy * co-existing high-grade ovarian cancer or another histology * history of prior malignancy with recurrence \<3 years from the time of enrollment * major surgery within 4 weeks * symptomatic brain metastases requiring steroids or other interventions * known sars-cov2 infection (clinical symptoms) ≤28 days prior to first dose of study therapy * for subjects with prior mek exposure, grade 4 toxicity deemed related to the mek inhibitor * active skin disorder that has required systemic therapy within the past year * history of rhabdomyolysis * concurrent ocular disorders * concurrent heart disease or severe obstructive pulmonary disease * subjects with the inability to swallow oral medications

Keywords: low grade serous ovarian cancer kras, kras wt
a study to follow patients with adult growth hormone deficiency (aghd) treated with sogroya® for long term safety information

Conditions: Adult Growth Hormone Deficiency

Summary: in this study, the general long-term safety and effectiveness of sogroya (somapacitan) in adults with growth hormone deficiency (aghd) being treated per normal clinical practice is looked into. in the study, information on side effects and how well sogroya (somapacitan) works during long term treatment in people with adult growth hormone deficiency (aghd) will be collected and analysed. participants will be treated with sogroya (somapacitan) as prescribed by the study doctor, in accordance with normal clinical practice. the study will last for 5-10 years, depending on when the participant join the study. the participant will be asked to complete two short questionnaires during every visit to the clinic. the questionnaires will collect information on the participant's well-being, work ability and ability to perform daily activities.


Eligibility criteria:
inclusion criteria: 1. signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. the decision to initiate treatment with commercially available sogroya (somapacitan) has been made by the participant and the treating physician before and independently from the decision to include the participant in this study. 3. male or female, age above or equal to 18 years assigned to sogroya (somapacitan) treatment at the time of signing informed consent. 4. diagnosis of adult growth hormone deficiency (aghd) as per local practice. exclusion criteria: 1. previous participation in this study. participation is defined as signed informed consent. 2. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. 3. participant with hypersensitivity to the active substance or to any of the excipients. 4. participant with active malignancy or in treatment for active pre-existing malignancy. 5. participant with acute critical illness, suffering from complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions per investigator judgement.
a study of stereotactic body radiation therapy (sbrt) without androgen deprivation therapy (adt) in people with unfavorable intermediate-risk prostate cancer

Conditions: Prostate Cancer

Summary: the researchers are doing this study to find out if stereotactic body radiation therapy (sbrt) without androgen deprivation therapy (adt) is an effective treatment approach for people with unfavorable intermediate-risk prostate. the researchers will see whether sbrt can prevent participants' cancer from coming back and/or spreading to other parts of the body. in addition, they will look closely at how safe and effective it is to rely on decipher test results for determining which patients would benefit from more extensive radiation treatments


Eligibility criteria:
inclusion criteria: * pathologically proven diagnosis of prostate adenocarcinoma within 12 months of enrollment * unfavorable intermediate risk prostate cancer by nccn 2021 risk stratification guidelines, including any of the following clinicopathologic features: * gleason score 4+3 * ≥ 50% biopsy cores positive * two or more of the following risk factors: * grade group 2 or 3 * ct2b-t2c * psa 10 - 20 ng/ml * able to undergo mri for initial staging and mr based radiation planning * sufficient biopsy tissue available for decipher genomic testing * prostate volume \< 90cc * ipss ≤ 20 * age ≥ 18 * kps ≥ or ecog 0-2 * estimated life expectancy \>5 years * willing and able to provide written informed consent and authorization for use and release of health and research study information (hipaa authorization) exclusion criteria: * radiographic t3-t4 detected on staging mpmri °must be "consistent with" (\>90% probability) or suspicious for/probable/probably (75%-90% probability) oft3-t4 disease determined by the reading radiologist. * evidence of distant metastases as determined by mri, pet, or ct imaging * evidence of pelvic lymph node involvement as determined by mri, pet, or ct imaging * prior treatment for prostate cancer including chemotherapy, surgery, or hormonal therapy * prior pelvic radiation * active second malignancy or past history of malignancies diagnosed within the last 2 years that requires active therapy and/or in remission, with the exception of resected non-melanoma skin cancers, non-muscle invasive bladder cancer, stage i head and neck cancer, or stage i colorectal cancer * turp or greenlight pvp within 6 months of enrollment * history of crohn's disease or ulcerative colitis

Keywords: unfavorable intermediate-risk prostate cancer stereotactic body radiation therapy (sbrt) 21-458
a prospective & retrospective study on ectopic lymphoid-like structures in chronic skins of autoimmune bullous diseases

Conditions: Autoimmune Bullous Disease

Summary: the purpose of this study is to identify the presence or absence of ectopic lymph node-like structures in skin lesions of patients with autoimmune bullous disease and the subtypes of the cells deposited there. in addition, this study clarifies the therapeutic effect of intralesional steroid injection in patients with pemphigus harboring ectopic lymph node-like structure.


Eligibility criteria:
inclusion criteria: \ prospective study inclusion criteria: 1. adults over 19 2. patietns who voluntarily signed the consent form 3. patients who are diagnosed with autoimmune bullous disease through clinical, histological and serological tests retrospective study inclusion criteria: 1. samples in human-derived banks from march 2013 to october 2018 2. patients who are diagnosed with autoimmune bullous disease through clinical, histological and serological tests 3. adults over 19 \ prospective study inclusion criteria: 1. adults over 19 2. patients who voluntarily signed the consent form 3. patients who have skin lesions harboring ectopic lymph node-like structure in a prospective or retrospective manner 4. patients who have chronic lesions sustained for more than 4 months during the treatment of systemic corticosteroids retrospective study inclusion criteria: 1. patients who have skin lesions harboring ectopic lymph node-like structure in a retrospective manner 2. paitents who have been treated for intralesional steroid injection 3. patients who have data of photography to compare the clinical effects before and after intralesional corticosteroid treatment. exclusion criteria: 1. patients who do not meet the criteria for autoimmune bullous disease

Keywords: els
pilot of abstats /aegis system for detecting motility abnormalities

Conditions: Motility Disorders

Summary: when compared to existing analyses: manometry, smart pill and lactulose breath testing, external acoustic esophago-gastro-intestinal surveillance (aegis) may identify unique audible patterns characteristic of features of gastroinestinal (gi) motility, gastric and small bowel contractions and emptying and small intestinal bacterial overgrowth (sibo). this research study is designed to test the capabilities of abstats/aegis to identify and associate symptoms and traditional diagnostics with sound readings and correlate this data with treatment outcomes and successes in standard of care.

in partnership with dr. william kaiser and the ucla wireless health institute, our research groups are developing and validating the diagnostic capabilities of device that conducts aegis. a belt (abstats) fits externally around the abdomen and is embedded with acoustic sensors, similar to "electronic stethoscopes." the investigational software is designed to continuously, safely, and comfortably monitor acoustic signals emanating from the esophagus, stomach, and intestines, and stores the data in a hipaa compliant hard drive. through the study of associating these readings with current diagnostics and treatments we anticipate that the aegis device will eventually provide clinically interpretable information that is immediately actionable. in this study, the abstats sensor will track signals in tandem with current techniques and standard of care treatments based on those diagnostics. aegis analysis could potentially refine, support, or even replace, existing costly and invasive techniques in the diagnosis of gastroparesis, intestinal psueodo-obstruction, colonic inertia, and disorders related to small intestinal bacterial overgrowth (sibo).

Eligibility criteria:
inclusion criteria: * ≥ 18 years old * scheduled for a small bowel manometry, smartpill, or lactulose hydrogen breath test in the cedars-sinai motility program exclusion criteria: * body mass index that is incompatible with placement of the belt (typically bmi greater than 45) * abdominal wall condition that disallows topical coverage as deemed by treating physician (eg abdominal wound, advanced cellulitis, draining ostomy etc) * inability to consent * have cognitive inability to follow directions
macro-scale estimators of covid-19's worldwide cases and deaths

Conditions: COVID19

Summary: in this study, investigators try to estimate covid-19 cases and deaths using countrywide annual macro-scale indicators (i.e., estimators) such as non-communicable disease data from who (who. int), social and economical indicators from un (un.org) and worldbank (worldbank.org), and covid-19 cases and deaths from worldometer (https://www.worldometers.info).

there are some known risk factors for the emergence and mortality of covid-19 cases. there are also some regulations and recommendations by healthcare executives and government officers such as wearing masks, social distance, staying at home, lockdowns, and so forth. on the other hand, there could be other social, economic, and health-related factors in the society level that discriminate between countries significantly in terms of having considerable differences regarding both the frequency and mortality of covid-19. the aim of the present study is to find out these social, economic, and health-related factors that could explain some significant portion of covid-19 cases and deaths worldwide. this study involves 171 countries of which required datasets are commonly available in the un, worldometer, and who. the investigators will obtain macro-scale indicators like non-communicable disease data from who (who. int), social and economical indicators from un (un.org) and worldbank (worldbank.org), and covid-19 data from worldometer (https://www.worldometers.info). the investigators will conduct statistical data analysis and create predictive models in order to determine indicators. the investigators will also consider that possible different models for explaining covid-19 cases and mortality in both common and different estimators could explain the variations in countrywide deaths and cases.

Eligibility criteria:
inclusion criteria: * all recorded cases by the authority exclusion criteria: * none
a study to evaluate the efficacy and safety of rosnilimab (anb030) in treatment of subjects with moderate-to-severe alopecia areata

Conditions: Alopecia Areata

Summary: efficacy and safety of rosnilimab (anb030) in subjects with moderate-to-severe alopecia areata

this is a phase 2, randomized, double-blind, placebo-controlled, parallel-group,multicenter study to evaluate the safety, tolerability, and efficacy of rosnilimab in subjects with alopecia areata (aa).this study also will evaluate the pharmacokinetics (pk) and pharmacodynamics (pd) of rosnilimab and evaluate the immunogenicity of rosnilimab in subjects with aa.

Eligibility criteria:
inclusion criteria: * male or nonpregnant, nonlactating female subject aged 18 to 75 years (inclusive) at the time of informed consent. * subjects with a clinical diagnosis of aa defined as having a salt score ≥ 50 and in which the current episode of hair loss is \> 24 weeks (without evidence of spontaneous terminal hair regrowth ≥ 10% within 24 weeks at the time of screening and baseline), but ≤ 8 years (from onset of current episode). exclusion criteria: * concomitant active systemic diseases (except stable thyroid diseases) that may cause hair loss (eg, lupus erythematosus, systemic sclerosis, celiac disease) that could interfere with the investigators' ability to evaluate the subject's response to therapy. * subject's cause of hair loss is indeterminable and/or in addition to aa they have concomitant causes of alopecia, such as traction alopecia, cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, advanced androgenetic alopecia (ie, ludwig type iii or norwood-hamilton stage ≥ v), telogen effluvium, trichotillomania, or diffuse aa (alopecia areata incognita). * known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status (eg, history of splenectomy).

Keywords: pd-1 receptor rosnilimab
syringe service based telemedicine and social network driven hiv prevention service implementation

Conditions: HIV Infections; Substance Use Disorders; Addiction; Opioid Use; Drug Use; Intravenous Drug Usage

Summary: the goal of this clinical trial is to evaluate the effectiveness of a social network intervention to recruit people who inject drugs and their networks for hiv testing and linkage to hiv prevention and treatment services in maryland. study aims are to determine the effectiveness of a social network driven intervention to increase: * hiv testing (primary); * prep knowledge; * uptake of hiv services and pre-exposure prophylaxis (prep); * uptake of medication for opioid use disorder (moud) initiation. eligible participants who access syringe service programs (ssps) serving two counties in maryland and their risk network members (nms) will be recruited using an established network inventory and coupon recruitment method. when an index successfully recruits nms, the index-nm cluster will be randomized to either a peer-educator intervention arm or an equal-attention control arm. index participants randomized to the peer-educator intervention arm will complete a training program adapted with stakeholder input to context that emphasizes effective communication, frequent hiv testing, and awareness of evidence-based hiv prevention and treatment services. an important innovation to the network intervention will be training indexes to use and distribute hiv self-test kits and naloxone to their nms. index participants randomized to the equal-attention control arm will receive training sessions focused on the opioid overdose epidemic and will not include any training to serve as a peer educator. all participants (indexes and nms) will complete study assessments at baseline and at 3 and 9 months. we will compare the peer-educator intervention group and the equal-attention control group on rates of hiv testing, knowledge of prep options and resources, and rates of initiation of hiv treatment, prep, and moud treatment since the previous assessment (past 3 or 6 months).


Eligibility criteria:
inclusion criteria: inclusion criteria for index participants: * aged 18 or older * self-reported injection drug use in the prior month * accessed services at the ssp in the prior 3 months * willing to undergo training and attend weekly booster group sessions * able to recruit at least 1 drug use network member (nm) into study * willing to talk with peers about pwid topics such as hiv prevention and care * not previously enrolled in the study as index or nm * english-speaking inclusion criteria for network member participants: * aged 18 or older * self-reported injection drug use in the prior month * have a valid coupon or able to recall the 3-digit id number * not previously enrolled in the study as index or nm * english-speaking exclusion criteria: • individuals lacking the capacity to consent

Keywords: injection drug use hiv prevention social networks